Clinical Trials

Shanton Pharma has received regulatory waivers from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), removing the need for additional pediatric…
Read More...

Boehringer Ingelheim has registered a new Phase III clinical trial to evaluate verducatib, an experimental oral medicine for people living with chronic obstructive pulmonary disease…
Read More...

EyePoint, Inc. (NASDAQ: EYPT) has announced topline results from its LUCIA Phase 3 clinical trial evaluating DURAVYU (vorolanib intravitreal insert) as a treatment for wet age-related…
Read More...

Roche has received approval from the U.S. Food and Drug Administration (FDA) for Enspryng (satralizumab) to treat adults with thyroid eye disease (TED). The approval introduces the…
Read More...

AstraZeneca and Ionis Pharmaceuticals have announced that their Phase III CARDIO-TTRansform trial evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid…
Read More...

Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The…
Read More...

uniQure has reported encouraging early clinical results from its experimental gene therapy AMT-260, offering new hope for patients living with refractory mesial temporal lobe epilepsy…
Read More...

Massive Bio and Optellum have announced a strategic collaboration designed to connect early lung cancer detection with faster access to clinical trials, potentially addressing one of…
Read More...

SystImmune and Bristol Myers Squibb have reported positive Phase 3 results for izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC),…
Read More...

British pharmaceutical company GSK has reported encouraging late-stage clinical trial results for bepirovirsen, an investigational therapy for chronic hepatitis B (CHB), raising hopes…
Read More...

Regeneron Pharmaceuticals reported encouraging early-stage results from a Phase 1/2 clinical trial evaluating Lynozyfic (linvoseltamab) in patients with relapsed or treatment-resistant…
Read More...

Global pharmaceutical company Merck & Co. has announced positive pivotal Phase 3 results for sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug…
Read More...

AstraZeneca announced positive interim results from the Phase III VOLGA clinical trial, showing that perioperative treatment with Imfinzi combined with neoadjuvant enfortumab vedotin…
Read More...

Madrigal Pharmaceuticals, Inc. has entered into an exclusive global licensing agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-PNPLA3, a clinical-stage…
Read More...

Akeso, Inc. has announced that its novel trispecific antibody candidate, AK150, has received Investigational New Drug (IND) clearance from the National Medical Products Administration…
Read More...

Vima Therapeutics has announced significant progress in the development of its experimental treatment for movement disorders, revealing that the first patient has been dosed in a Phase…
Read More...

Biotechnology companies Akeso, Inc. and INOVIO have announced a clinical trial collaboration and supply agreement to evaluate a new combination immunotherapy approach for glioblastoma…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim…
Read More...